Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Onyx Pharmaceuticals has filed a complaint against Bayer Corporation and Bayer A.G., in the District Court of California, claiming its rights to a Phase 2 anti-cancer compound discovered during a joint research between both the companies.
Subscribe to our email newsletter
In its complaint, Onyx seeks a declaration that fluoro-sorafenib is a jointly-owned collaboration compound under the Bayer/Onyx collaboration agreement, together with other remedies.
Onyx affirmed that it continues to collaborate with Bayer in the development and commercialisation of Nexavar.
Onyx was recently advised that the compound, fluoro-sorafenib, is a variant of Nexavar (sorafenib) tablets and has the same chemical structure as Nexavar, except that a single fluorine atom has been substituted for a hydrogen atom.
The new molecule was identified in 1998 during the research collaboration period by the companies’ joint research teams.
Discussions with Bayer regarding Onyx’s rights to fluoro-sorafenib, under the companies’ 1994 collaboration agreement, were not productive.
Greg Giotta, Vice President and Chief Legal Counsel of Onyx, said, Onyx and Bayer have had a long-standing and successful collaboration for more than 15 years. Against that background, we are disappointed that we could not resolve this matter and believe this complaint is necessary to protect our rights and the rights of our shareholders under the collaboration agreement.